Literature DB >> 9635475

Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome.

Y Sekijima1, S Ikeda, T Tokuda, S Satoh, H Hidaka, E Hidaka, M Ishikawa, N Yanagisawa.   

Abstract

We investigated the exact prevalence of dementia of Alzheimer type (DAT) and apolipoprotein E (ApoE) phenotypes in 106 Japanese Down's syndrome (DS) patients. Among these patients 16 were diagnosed as having DAT. The prevalence of DAT was 0% in the 30- to 39-year-old group, 16% in the 40- to 49-year-old group, and 38% in those over 50 years old. The frequency of the epsilon4 allele in DS patients with DAT was 18.8%, which was considerably higher than that of nondemented DS patients (4.5%) and Japanese nondemented controls (6.7%). Especially, the frequency of the epsilon4 allele in DS patients who developed DAT under 50 years was significantly higher (28.6%). DS patients certainly develop DAT at earlier ages but the prevalence of DAT in each group of patients was lower than previously recognized. It is very likely that the ApoE epsilon4 is a risk factor for DAT even in DS patients with a genetic predisposition to Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9635475     DOI: 10.1159/000007940

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  10 in total

Review 1.  The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review.

Authors:  R A Nixon; A M Cataldo; P M Mathews
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

Review 2.  Stem and progenitor cell dysfunction in human trisomies.

Authors:  Binbin Liu; Sarah Filippi; Anindita Roy; Irene Roberts
Journal:  EMBO Rep       Date:  2014-12-17       Impact factor: 8.807

3.  Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome.

Authors:  Maria Florencia Iulita; Diana Garzón Chavez; Maria Klitgaard Christensen; Natalia Valle Tamayo; Oleguer Plana-Ripoll; Sonja A Rasmussen; Marta Roqué Figuls; Daniel Alcolea; Laura Videla; Isabel Barroeta; Bessy Benejam; Miren Altuna; Concepción Padilla; Jordi Pegueroles; Susana Fernandez; Olivia Belbin; María Carmona-Iragui; Rafael Blesa; Alberto Lleó; Alexandre Bejanin; Juan Fortea
Journal:  JAMA Netw Open       Date:  2022-05-02

4.  Significant effect of APOE epsilon 4 genotype on the risk of dementia in Alzheimer's disease and mortality in persons with Down syndrome.

Authors:  V P Prasher; S G Sajith; S D Rees; A Patel; S Tewari; N Schupf; W B Zigman
Journal:  Int J Geriatr Psychiatry       Date:  2008-11       Impact factor: 3.485

Review 5.  Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments.

Authors:  Paula Castro; Shahid Zaman; Anthony Holland
Journal:  J Neurol       Date:  2016-10-24       Impact factor: 4.849

6.  Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP.

Authors:  Dean Nizetic; Christopher L Chen; Wanjin Hong; Edward H Koo
Journal:  Front Behav Neurosci       Date:  2015-12-01       Impact factor: 3.558

Review 7.  Rivastigmine for dementia in people with Down syndrome.

Authors:  Monica Mohan; Cathy Bennett; Peter K Carpenter
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

Review 8.  Memantine for dementia in people with Down syndrome.

Authors:  Monica Mohan; Cathy Bennett; Peter K Carpenter
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

Review 9.  Galantamine for dementia in people with Down syndrome.

Authors:  Monica Mohan; Cathy Bennett; Peter K Carpenter
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

Review 10.  Donepezil for dementia in people with Down syndrome.

Authors:  Monica Mohan; Peter K Carpenter; Cathy Bennett
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.